Targeting ferroptosis with the lipoxygenase inhibitor PTC-041 as a therapeutic strategy for the treatment of Parkinson’s disease
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0309893 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Angela Minnella und 9 weiteren Autor:innen. Beteiligte Einrichtung: PTC Therapeutics, Mountain View, California, United States of America. Hauptthemen laut MEDLINE: Ferroptosis, Lipoxygenase Inhibitors, Parkinson Disease. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Parkinson’s disease is the second most common neurodegenerative disorder, affecting nearly 10 million people worldwide. Ferroptosis, a recently identified form of regulated cell death characterized by 15-lipoxygenase-mediated hydroperoxidation of membrane lipids, has been implicated in neurodegenerative disorders including amyotrophic lateral sclerosis and Parkinson’s disease. Pharmacological inhibition of 15 -lipoxygenase to prevent iron- and lipid peroxidation-associated ferroptotic cell death is a rational strategy for the treatment of Parkinson’s disease. We report here the characterization of PTC-041 as an anti-ferroptotic reductive lipoxygenase inhibitor developed for the treatment of Parkinson’s disease. In these studies, PTC-041 potently protects primary human Parkinson’s disease patient-derived fibroblasts from lipid peroxidation and subsequent ferroptotic cell death and prevents ferroptosis-related neuronal loss and astrogliosis in primary rat neuronal cultures. Additionally, PTC-041 prevents ferroptotic-mediated α-synuclein protein aggregation and nitrosylation in vitro, suggesting a potential role for anti-ferroptotic lipoxygenase inhibitors in mitigating pathogenic aspects of synucleinopathies such as Parkinson’s disease. We further found that PTC-041 protects against synucleinopathy in vivo, demonstrating that PTC-041 treatment of Line 61 transgenic mice protects against α-synuclein aggregation and phosphorylation as well as prevents associated neuronal and non-neuronal cell death. Finally, we show that. PTC-041 protects against 6-hydroxydopamine-induced motor deficits in a hemiparkinsonian rat model, further validating the potential therapeutic benefits of lipoxygenase inhibitors in the treatment of Parkinson’s disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- PTC Therapeutics, Mountain View, California, United States of America.
- PTC Therapeutics, Warren, New Jersey, United States of America.
- Cure Parkinson's, London, England, United Kingdom.
ORCID-Profile: Jeffrey K Trimmer
Zitieren
APA
Minnella, A., McCusker, K. P., Amagata, A., Trias, B., Weetall, M., Latham, J. C., O'Neill, S., Wyse, R. K., Klein, M. B., & Trimmer, J. K. (2024). Targeting ferroptosis with the lipoxygenase inhibitor PTC-041 as a therapeutic strategy for the treatment of Parkinson’s disease. PLOS ONE. https://doi.org/10.1371/journal.pone.0309893
Vancouver
Minnella A, McCusker KP, Amagata A, Trias B, Weetall M, Latham JC, et al. Targeting ferroptosis with the lipoxygenase inhibitor PTC-041 as a therapeutic strategy for the treatment of Parkinson’s disease. PLOS ONE. 2024. doi:10.1371/journal.pone.0309893
BibTeX
@article{Minnella2024,
author = {Minnella, Angela and McCusker, Kevin P and Amagata, Akiko and Trias, Beatrice and Weetall, Marla and Latham, Joey C and O'Neill, Sloane and Wyse, Richard K and Klein, Matthew B and Trimmer, Jeffrey K},
title = {Targeting ferroptosis with the lipoxygenase inhibitor PTC-041 as a therapeutic strategy for the treatment of Parkinson’s disease},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0309893}
}
EUVIMED